Three top-rated medical stocks are set to report fourth-quarter earnings later this month. Valeant Pharmaceuticals (VRX) has been in a steady uptrend since retaking a 147.49 buy point Jan. 8 in big volume. That morning Valeant announced updated guidance on fourth-quarter results and looked ahead to 2015. Full Q4 results will be reported Feb. 24 before the market opens.